ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.

Abstract

During the last decades, the pharmacotherapy of heart failure (HF) has changed dramatically. Large-scale trials have been conducted that have indisputably shown the efficacy of angiotensin-converting enzyme inhibitors (ACE-I) and beta-adrenergic receptor blockers (β-blockers). These and other therapies have improved the overall outcome of patients with HF, although prognosis remains bleak.